Climb Bio, Inc.
No SEC Form 4 filings for $CLYM in the last 30 days.
Climb Bio, Inc. (CLYM) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 clym-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Climb Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates CLYM116 Phase 1 data in healthy volunteers to be presented at R&D Spotlight Event on September 3, 2026 Anticipate CLYM116 Phase 2 trial in
Climb Bio, Inc. (CLYM) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K false 0001768446 0001768446 2026-06-29 2026-06-29 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29,
Climb Bio, Inc. (CLYM) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-1.1 2 d92589dex11.htm EX-1.1 EX-1.1 Exhibit 1.1 OPEN MARKET SALE AGREEMENT SM June 12, 2026 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Climb Bio, Inc., a Delaware corporation (the “ Company ”), proposes, subject to the terms and conditions
Over the past 7 days, alphai's AI scored 1 news story mentioning CLYM (Climb Bio, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent CLYM coverage spans financial news, corporate actions and earnings.
The filing provides fresh, decision-relevant pipeline timing plus a quantified cash runway extension, which can shift biotech risk pricing.
Board change with a defined equity grant; likely modest near-term impact, but it updates governance/compensation expectations.
The company has set up an at-the-market (ATM) equity issuance program, which can increase near-term dilution over time.
The filing is primarily governance/compensation related (director/officer appointments and equity plan mechanics), with limited direct signal on near-term fundamentals.
The news highlights leadership stability and recent management updates at Climb Bio, which could positively influence investor confidence and stock valuation.
alphai scores every news story that mentions CLYM with an AI model for sentiment and relevance, and aggregates insider trades from Climb Bio, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Climb Bio, Inc. (CLYM) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 clym-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Climb Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates CLYM116 Phase 1 data in healthy volunteers to be presented at R&D Spotlight Event on September 3, 2026 Anticipate CLYM116 Phase 2 trial in
6 min readClimb Bio, Inc. (CLYM) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K false 0001768446 0001768446 2026-06-29 2026-06-29 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29,
2 min readClimb Bio, Inc. (CLYM) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-1.1 2 d92589dex11.htm EX-1.1 EX-1.1 Exhibit 1.1 OPEN MARKET SALE AGREEMENT SM June 12, 2026 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Climb Bio, Inc., a Delaware corporation (the “ Company ”), proposes, subject to the terms and conditions
2 min readClimb Bio, Inc. (CLYM) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-99.1 2 d72849dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 CLIMB BIO, INC. 2021 EQUITY INCENTIVE PLAN ADOPTED BY THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS: July 26, 2021 APPROVED BY THE STOCKHOLDERS: July 29, 2021 1. GENERAL. (a) Successor to and Continuation of Prior Pla
6 min readThis article provides an analysis of Climb Bio, Inc.'s (CLYM) leadership and management team. It details compensation for CEO Aoife Brennan, management and board tenure, and lists recent company updates including executive changes, regulatory designations, and financial activities. The report also compares CEO compensation to market averages and outlines the company's financial data as of December 2025.
5 min readPreclinical data for CLYM116, anti-APRIL monoclonal antibody, highlight favorable pharmacokinetic and pharmacodynamic profile, supporting development for IgA nephropathy ...
3 min readHere is how Climb Bio, Inc. (CLYM) and Idexx Laboratories (IDXX) have performed compared to their sector so far this year.
3 min readWELLESLEY HILLS, Mass., Sept. 04, 2025 ( GLOBE NEWSWIRE ) -- Climb Bio, Inc. ( Nasdaq: CLYM ) , a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced details for the CLYM116 webcast event, which is set for Monday, September 29, 2025, at 8:00 ...
2 min readShould investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?
3 min readHere is how Climb Bio, Inc. (CLYM) and Cencora (COR) have performed compared to their sector so far this year.
3 min read
